A significant contribution to the research in mutation landscape of CLL reported a few years ago that BIRC3 abnormalities associate to an inferior outcome in the LLC0405 protocol [39]. The gene discussed is BIRC3; the disease is B-cell chronic lymphocytic leukemia.